{"id":5138,"date":"2026-03-10T15:03:31","date_gmt":"2026-03-10T15:03:31","guid":{"rendered":"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/"},"modified":"2026-03-10T15:03:31","modified_gmt":"2026-03-10T15:03:31","slug":"vertex-passes-key-test-in-quest-to-treat-kidney-diseases","status":"publish","type":"post","link":"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/","title":{"rendered":"Vertex passes key test in quest to treat kidney diseases"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div id=\"RegularArticle-ArticleBody-5\" data-module=\"ArticleBody\" data-test=\"articleBody-2\" data-analytics=\"RegularArticle-articleBody-5-2\"><span class=\"HighlightShare-hidden\" style=\"top:0;left:0\"\/><\/p>\n<div class=\"InlineImage-imageEmbed\" id=\"ArticleBody-InlineImage-107347177\" data-test=\"InlineImage\">\n<div class=\"InlineImage-wrapper\">\n<div>\n<p>A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston.<\/p>\n<p>Brian Snyder | Reuters<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"group\">\n<p><span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-1\"><a href=\"https:\/\/www.cnbc.com\/quotes\/VRTX\/\">Vertex Pharmaceuticals <\/a><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"\/><\/button><\/span><\/span><\/span>said its experimental drug for a rare kidney condition succeeded in a Phase 3 trial, a crucial step in the company&#8217;s path to diversify beyond its main drugs for cystic fibrosis.\u00a0<\/p>\n<p>The Boston-based drugmaker on Monday said its drug for immunoglobulin A nephropathy, povetacicept, decreased levels of a marker of the autoimmune condition by 52% in a late-stage trial. That passed the bar analysts had set for Vertex&#8217;s drug to compete with a recently approved treatment from Japan-based Otsuka and another in the pipeline from U.S.-based biotech <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-2\"><a href=\"https:\/\/www.cnbc.com\/quotes\/VERA\/\">Vera Therapeutics<\/a><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"\/><\/button><\/span><\/span><\/span>.\u00a0Shares of Vertex rose more than 9% on Tuesday. <\/p>\n<p>Vertex&#8217;s successful trial is an important first step in unlocking a new franchise in kidney disease, said Cantor Fitzgerald analyst Carter Gould. Vertex is developing two drugs behind povetacicept, and Gould sees the three together generating more than $10 billion in revenue a year. That could rival Vertex&#8217;s cystic fibrosis franchise, which brought in more than $11 billion in sales last year.\u00a0<\/p>\n<p>&#8220;You don&#8217;t really have to look too hard to connect the dots and say this is pretty meaningful white space they could be growing into,&#8221; Gould said.\u00a0<\/p>\n<p>Vertex transformed the treatment for cystic fibrosis with a portfolio of drugs for the inherited lung disorder, but the company has repeatedly faced questions about whether it could replicate that success in other conditions. The company in recent years expanded into <a href=\"https:\/\/www.cnbc.com\/2023\/12\/08\/casgevy-first-crispr-gene-editing-treatment-approved-in-us.html\">blood disorders<\/a> with the approval of its gene-editing treatment Casgevy and <a href=\"http:\/\/google.com\/search?q=cnbc+vertex+pain&amp;amp;rlz=1C1GCEB_enUS1199US1199&amp;amp;oq=cnbc+vertex+pain&amp;amp;gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIHCAEQIRigATIHCAIQIRigATIHCAMQIRigATIHCAQQIRifBTIHCAUQIRifBTIHCAYQIRifBTIHCAcQIRifBTIHCAgQIRifBTIHCAkQIRifBdIBCDIyNThqMGo5qAIAsAIB&amp;amp;sourceid=chrome&amp;amp;ie=UTF-8\" target=\"_blank\">acute pain<\/a> with its drug Journavx. Neither has so far been a runaway success, leaving Vertex to search for other opportunities to expand. <\/p>\n<p>In 2024, Vertex paid nearly $5 billion to acquire Alpine Immune Sciences and its lead program, povetacicept. The drug could treat a rare autoimmune condition known as IgAN that prevents the kidneys from functioning properly, sometimes leading to patients needing dialysis or even transplant. Vertex also plans to test the drug for several other kidney conditions. <\/p>\n<p>The company expects to complete its application with the U.S. Food and Drug Administration for povetacicept in IgAN by the end of this month, with approval possible later this year with the use of a voucher for priority review.<\/p>\n<\/div>\n<div class=\"ArticleBody-googlePreferredSourceContainer\" data-module=\"GooglePreferredSource\" data-id=\"RegularArticle-GooglePreferredSource-5\"><a href=\"https:\/\/www.google.com\/preferences\/source?q=https:\/\/www.cnbc.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.<\/a><\/div>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.cnbc.com\/2026\/03\/10\/vertex-kidney-drug-povetacicept-succeeds-trial-igan.html\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston. Brian Snyder | Reuters Vertex Pharmaceuticals said its experimental drug for a rare kidney condition succeeded in a Phase 3 trial, a crucial step in the company&#8217;s path to diversify beyond its main drugs for cystic fibrosis.\u00a0 The Boston-based drugmaker on&#8230;<\/p>\n<p class=\"more-link-wrap\"><a href=\"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/\" class=\"more-link\">Read More<span class=\"screen-reader-text\"> &ldquo;Vertex passes key test in quest to treat kidney diseases&rdquo;<\/span> &raquo;<\/a><\/p>\n","protected":false},"author":1,"featured_media":5139,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/107347177-17024876422019-10-23t192640z_180367507_rc14151b5800_rtrmadp_0_vertex-pharms-fda.jpeg?v=1721666564&w=1920&h=1080","fifu_image_alt":"","footnotes":""},"categories":[4],"tags":[4049,73,4046,77,4048,4047,70,4045,2232,4044,4043],"class_list":["post-5138","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-baxter-international-inc","tag-biotech-and-pharmaceuticals","tag-boston","tag-business-news","tag-davita-inc","tag-fresenius-medical-care-ag","tag-health-care-industry","tag-ishares-biotechnology-etf","tag-spdr-sp-biotech-etf","tag-vera-therapeutics-inc","tag-vertex-pharmaceuticals-inc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.8 (Yoast SEO v22.1) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Vertex passes key test in quest to treat kidney diseases - Breaking News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vertex passes key test in quest to treat kidney diseases\" \/>\n<meta property=\"og:description\" content=\"A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston. Brian Snyder | Reuters Vertex Pharmaceuticals said its experimental drug for a rare kidney condition succeeded in a Phase 3 trial, a crucial step in the company&#8217;s path to diversify beyond its main drugs for cystic fibrosis.\u00a0 The Boston-based drugmaker on...Read More &ldquo;Vertex passes key test in quest to treat kidney diseases&rdquo; &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Breaking News\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-10T15:03:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/image.cnbcfm.com\/api\/v1\/image\/107347177-17024876422019-10-23t192640z_180367507_rc14151b5800_rtrmadp_0_vertex-pharms-fda.jpeg?v=1721666564&w=1920&h=1080\" \/>\n<meta name=\"author\" content=\"Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/image.cnbcfm.com\/api\/v1\/image\/107347177-17024876422019-10-23t192640z_180367507_rc14151b5800_rtrmadp_0_vertex-pharms-fda.jpeg?v=1721666564&w=1920&h=1080\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/\"},\"author\":{\"name\":\"Admin\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a\"},\"headline\":\"Vertex passes key test in quest to treat kidney diseases\",\"datePublished\":\"2026-03-10T15:03:31+00:00\",\"dateModified\":\"2026-03-10T15:03:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/\"},\"wordCount\":407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\"},\"keywords\":[\"Baxter International Inc\",\"Biotech and Pharmaceuticals\",\"Boston\",\"business news\",\"DaVita Inc\",\"Fresenius Medical Care AG\",\"Health care industry\",\"iShares Biotechnology ETF\",\"Spdr S&amp;P Biotech Etf\",\"Vera Therapeutics Inc\",\"Vertex Pharmaceuticals Inc\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/\",\"url\":\"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/\",\"name\":\"Vertex passes key test in quest to treat kidney diseases - Breaking News\",\"isPartOf\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#website\"},\"datePublished\":\"2026-03-10T15:03:31+00:00\",\"dateModified\":\"2026-03-10T15:03:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ventil.rs\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vertex passes key test in quest to treat kidney diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ventil.rs\/blog\/#website\",\"url\":\"https:\/\/ventil.rs\/blog\/\",\"name\":\"Breaking News\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ventil.rs\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\",\"name\":\"Breaking News\",\"url\":\"https:\/\/ventil.rs\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png\",\"contentUrl\":\"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png\",\"width\":1445,\"height\":591,\"caption\":\"Breaking News\"},\"image\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a\",\"name\":\"Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g\",\"caption\":\"Admin\"},\"sameAs\":[\"https:\/\/ventil.rs\/blog\"],\"url\":\"https:\/\/ventil.rs\/blog\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vertex passes key test in quest to treat kidney diseases - Breaking News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Vertex passes key test in quest to treat kidney diseases","og_description":"A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston. Brian Snyder | Reuters Vertex Pharmaceuticals said its experimental drug for a rare kidney condition succeeded in a Phase 3 trial, a crucial step in the company&#8217;s path to diversify beyond its main drugs for cystic fibrosis.\u00a0 The Boston-based drugmaker on...Read More &ldquo;Vertex passes key test in quest to treat kidney diseases&rdquo; &raquo;","og_url":"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/","og_site_name":"Breaking News","article_published_time":"2026-03-10T15:03:31+00:00","og_image":[{"url":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/107347177-17024876422019-10-23t192640z_180367507_rc14151b5800_rtrmadp_0_vertex-pharms-fda.jpeg?v=1721666564&w=1920&h=1080"}],"author":"Admin","twitter_card":"summary_large_image","twitter_image":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/107347177-17024876422019-10-23t192640z_180367507_rc14151b5800_rtrmadp_0_vertex-pharms-fda.jpeg?v=1721666564&w=1920&h=1080","twitter_misc":{"Written by":"Admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/#article","isPartOf":{"@id":"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/"},"author":{"name":"Admin","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a"},"headline":"Vertex passes key test in quest to treat kidney diseases","datePublished":"2026-03-10T15:03:31+00:00","dateModified":"2026-03-10T15:03:31+00:00","mainEntityOfPage":{"@id":"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/"},"wordCount":407,"commentCount":0,"publisher":{"@id":"https:\/\/ventil.rs\/blog\/#organization"},"keywords":["Baxter International Inc","Biotech and Pharmaceuticals","Boston","business news","DaVita Inc","Fresenius Medical Care AG","Health care industry","iShares Biotechnology ETF","Spdr S&amp;P Biotech Etf","Vera Therapeutics Inc","Vertex Pharmaceuticals Inc"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/ventil.rs\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/","url":"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/","name":"Vertex passes key test in quest to treat kidney diseases - Breaking News","isPartOf":{"@id":"https:\/\/ventil.rs\/blog\/#website"},"datePublished":"2026-03-10T15:03:31+00:00","dateModified":"2026-03-10T15:03:31+00:00","breadcrumb":{"@id":"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ventil.rs\/blog\/health\/vertex-passes-key-test-in-quest-to-treat-kidney-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ventil.rs\/blog\/"},{"@type":"ListItem","position":2,"name":"Vertex passes key test in quest to treat kidney diseases"}]},{"@type":"WebSite","@id":"https:\/\/ventil.rs\/blog\/#website","url":"https:\/\/ventil.rs\/blog\/","name":"Breaking News","description":"","publisher":{"@id":"https:\/\/ventil.rs\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ventil.rs\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ventil.rs\/blog\/#organization","name":"Breaking News","url":"https:\/\/ventil.rs\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png","contentUrl":"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png","width":1445,"height":591,"caption":"Breaking News"},"image":{"@id":"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a","name":"Admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g","caption":"Admin"},"sameAs":["https:\/\/ventil.rs\/blog"],"url":"https:\/\/ventil.rs\/blog\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/posts\/5138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/comments?post=5138"}],"version-history":[{"count":0,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/posts\/5138\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/media\/5139"}],"wp:attachment":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/media?parent=5138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/categories?post=5138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/tags?post=5138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}